Taysha Gene (TSHA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.13
- EPS estimate
- −$0.11
- EPS surprise
- −14.74%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $680,000.00
- Reported
- Aug 11, 2026
Taysha reported Q2 2026 results on August 11, 2026. It posted a loss of $0.13 per share, wider than the estimated $0.11 loss, a miss of 14.74%. The table gives no revenue figure for the quarter, against an estimate of $680,000. Compared with Q2 2025, the loss widened from $0.09 per share.
Taysha posted a loss in 19 of the 20 quarters in the table; the exception was a $0.26 profit in Q4 2023. Losses narrowed sharply over the record. Annual losses per share went from $3.78 in 2022 to $1.33 in 2023, $0.36 in 2024 and $0.34 in 2025. Since the start of 2024, quarterly results have stayed between a $0.07 and a $0.13 loss. Revenue has been small and irregular, from $1.1 million to $5.5 million in the quarters that show it, with the high in Q4 2025. Taysha beat the EPS estimate in nine of the last 20 quarters and missed in 11, including the last two.
Taysha reported Q3 between November 4 and November 14 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether the loss stays between $0.07 and $0.13 per share.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.11 | −$0.13 | −14.74% | $0.00 | SEC |
| Q1 2026 | May 6, 2026 | −$0.10 | −$0.12 | −24.10% | $0.00 | SEC |
| Q4 2025 | Mar 19, 2026 | −$0.10 | −$0.08 | +16.32% | $5.5M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.09 | −$0.09 | −1.01% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.08 | −$0.09 | −15.53% | $2.0M | SEC |
| Q1 2025 | May 15, 2025 | −$0.09 | −$0.08 | +8.68% | $2.3M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.08 | −$0.07 | +13.90% | $2.0M | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.09 | −$0.10 | −15.34% | $1.8M | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.16 | −$0.09 | +42.68% | $1.1M | SEC |
| Q1 2024 | May 14, 2024 | −$0.11 | −$0.10 | +6.80% | $3.4M | SEC |
| Q4 2023 | Mar 19, 2024 | −$0.11 | $0.26 | +331.76% | $3.6M | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.17 | −$0.93 | −438.51% | $4.7M | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.31 | −$0.38 | −22.15% | $2.4M | SEC |
| Q1 2023 | May 11, 2023 | −$0.36 | −$0.28 | +21.50% | $4.7M | SEC |
| Q4 2022 | Mar 28, 2023 | −$0.40 | −$0.99 | −148.06% | $2.5M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.82 | −$0.64 | +21.64% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$1.04 | −$0.84 | +19.22% | $0.00 | SEC |
| Q1 2022 | May 16, 2022 | −$1.08 | −$1.31 | −21.46% | $0.00 | SEC |
| Q4 2021 | Mar 31, 2022 | −$1.26 | −$1.32 | −5.16% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$1.08 | −$1.35 | −25.15% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Taysha Gene (TSHA) last report earnings?
Taysha Gene last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did TSHA beat earnings estimates?
No. Taysha Gene reported EPS of −$0.13 for Q2 2026 against a −$0.11 estimate — a 14.74% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.